Feb 28 ⢠Let's discuss anything here
đ¨ BREAKING: The âToo Dangerousâ Molecule Is About to Become a Miracle đ¨
They said it was risky.
They said it was illegal.
They said it was counterfeit, contaminated, reckless, life-threatening.
Now?
Theyâre preparing to patent it, brand it, and call it revolutionary.
𧏠The Data Theyâre Celebrating
Eli Lillyâs Phase 3 TRIUMPH-4 data on retatrutide shows:
đ 28.7% average body-weight reduction at 68 weeks (12 mg dose)
𦵠Significant reduction in knee pain (WOMAC improvements)
â¤ď¸ Improvements in triglycerides, non-HDL cholesterol, hs-CRP, and systolic BP
đĽ ~23â24% of participants lost âĽ35% body weight (bariatric-range outcomes)
Thatâs not incremental.
Thatâs surgical territory.
And yes, tolerability issues were there:
Nausea ~38â43%
Diarrhea ~33â35%
Vomiting ~20%
Discontinuation rates up to ~18%
New signal: dysesthesia
Some participants reportedly stopped because they lost too much weight.
Let that sink in.
âď¸ Now Remember the Messaging From Not Long AgoâŚ
Before commercial approval was realistic, the narrative was very different.
The tone was:
âUnapproved GLP-1 products are dangerous.â
âCompounded versions cause hospitalizations.â
âResearch-use ingredients are illegal and harmful.â
âOnline sales = counterfeit, contamination, overdoses.â
Regulators and corporate PR leaned heavily into:
Counterfeit scare language
Hospitalization statistics
Cease-and-desist campaigns
Litigation against telehealth and compounders
Anything outside the branded channel?
Framed as reckless.
Even retatrutide as an API was explicitly warned against in FDA communications.
The emotional positioning was clear:
If itâs not ours, itâs unsafe.
đ And Now?
Now the same molecule is being positioned as:
Historic
Breakthrough
Bariatric-level
Cardiometabolically transformative
Soon it will likely be:
Patented
Exclusively distributed
Marketed as the future of obesity treatment
âWell tolerated and effective when used appropriatelyâ
Same compound.
Different control.
đ§ The Pattern
This isnât about denying safety concerns.
Large-scale human data matters.
Standardization matters.
But the pattern is worth noticing:
Demonize early ecosystem access.
Frame non-corporate channels as existential risk.
Secure regulatory dominance.
Reintroduce the compound as innovation.
Blur vision long enough.
Capture the molecule.
Rewrite the story.
đ Why This Matters
Retatrutide may genuinely be one of the most powerful metabolic agents ever studied.
But if you donât track narrative shifts, youâll think:
The molecule changed.
The science changed.
The risk suddenly vanished.
In reality, what changed is who controls it.
1
1 comment
đ¨ BREAKING: The âToo Dangerousâ Molecule Is About to Become a Miracle đ¨
skool.com/pioneers-of-human-evolution-7743
Pioneers of Human Evolution
Level up with a crew of biohackers and go-getters. Weâre breaking limits, hacking performance, and crushing goals!
Leaderboard (30-day)
1
+30
2
+22
3
+17
4
+15
5
+14
Powered by